A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma-Reference-Cited by-同舟云学术

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma

Published:2014-11-17 Issue:6 Volume:168 Page:811-819
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Foss Francine¹,Advani Ranjana²,Duvic Madeleine³,Hymes Kenneth B.⁴,Intragumtornchai Tanin⁵,Lekhakula Arnuparp⁶,Shpilberg Ofer⁷,Lerner Adam⁸,Belt Robert J.⁹,Jacobsen Eric D.¹⁰,Laurent Guy¹¹,Ben-Yehuda Dina¹²,Beylot-Barry Marie¹³,Hillen Uwe¹⁴,Knoblauch Poul¹⁵,Bhat Gajanan¹⁶,Chawla Shanta¹⁶,Allen Lee F.¹⁶,Pohlman Brad¹⁷

Affiliation:

1. Yale Cancer Center; New Haven CT USA

2. Stanford University; Stanford CA USA

3. M.D. Anderson Cancer Center; Houston TX USA

4. Cancer Institute; New York University; New York NY USA

5. Department of Medicine; Chulalongkorn Hospital; Bangkok Thailand

6. Department of Medicine; Songlanagarind Hospital; Songkhla Thailand

7. Haematology; Rabin Medical Centre; Beilinson Hospital; Davidoff Cancer Centre and Sackler School of Medicine; Tel Aviv University; Petach Tikva Israel

8. Boston Medical Center; Boston MA USA

9. Kansas City Cancer Center; Kansas City MO USA

10. Dana-Farber Cancer Institute; Boston MA USA

11. Hopital Purpan; Toulouse France

12. Division of Haematology; Hadassah-Hebrew University Medical Centre; Jerusalem Israel

13. Hopital du Haut-Leveque; Universite Bordeaux; Pessac France

14. Universitatsklinikum Essen; Essen Germany

15. Topotarget; Copenhagen Denmark

16. Spectrum Pharmaceuticals; Irvine CA USA

17. Hematologic Oncology and Blood Disorders; Cleveland Clinic Taussig Cancer Institute; Cleveland OH USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13222/fullpdf

Reference30 articles.

1. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project;Armitage;Journal of Clinical Oncology,1998

2. Rational combinations using HDAC inhibitors;Bots;Clinical Cancer Research,2009

3. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications;Campo;Blood,2011

4. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

5. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral T-cell lymphoma: From biology to practice to the future;Cancer Treatment Reviews;2024-09

2. Romidepsin and Afatinib Abrogate Jak–Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma;Journal of Investigative Dermatology;2024-07

3. Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T‐cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report;Clinical Case Reports;2024-07

4. Advances in targeting histone deacetylase for treatment of solid tumors;Journal of Hematology & Oncology;2024-05-31

5. Advances in the pharmacological management of cutaneous T-cell lymphoma;Expert Opinion on Pharmacotherapy;2024-05-02